Pay in 4 interest-free payments of $30.00 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
) potently inhibits CENP-E motor function
and β-adrenoceptors
Comparative pharmacokinetics of levamisole-oxyclozanide combination in sheep and goats following per os administration
InChi: InChI=1S/C12H12N6/c1-7-9(18-12-14-2-3-15-12)4-8(5-13)11-10(7)16-6-17-11/h4
91(20):13080-13087
VU0364572 (trifluoroacetate salt) 247egeline ) potently inhibits CENP-E motorIC50: 477 172 nM VU0364572 is a M1 agonist. Alzheimer's disease (AD) is the leading cause of dementia worldwide, and no disease modifying therapy is availables. Selective M1 muscarinic acetylcholine receptor activation is an attractive mechanism for AD therapy since M1 mediates key effects on cognition, memory, and behavior and has potential for disease modifying effects on A formation and tau phosphorylation. In vitro: Previous study found that
US$ 75.00
US$ 125.00
US$ 65.00
US$ 145.00
US$ 180.00